A Valuation Metrics
A Stock Price Metrics
A Dividend Metrics
A Growth Rate Metrics
A Discounted Cash Flow Metrics
| Fair Value Price | $74.94 |
| Margin of Safety | (44.69%) |
A Revenue Metrics
A PE Ratio Metrics
| PE Ratio | 27.20 |
| PE Ratio Avg TTM | 29.35 |
| PE Ratio Avg 3Y | 29.81 |
| Current VS TTM Avg | -7.34% |
| Current VS 3Y Avg | -8.75% |
| Current VS 5Y Avg | -17.05% |
A PS Ratio Metrics
| PS Ratio | 5.32 |
| PS Ratio Avg TTM | 5.30 |
| PS Ratio Avg 3Y | 5.53 |
| Current VS TTM Avg | +0.45% |
| Current VS 3Y Avg | -3.79% |
| Current VS 5Y Avg | -10.99% |
A PB Ratio Metrics
| PB Ratio | 5.40 |
| PB Ratio Avg TTM | 5.57 |
| PB Ratio Avg 3Y | 6.12 |
| Current VS TTM Avg | -3.02% |
| Current VS 3Y Avg | -11.71% |
| Current VS 5Y Avg | -22.72% |
A Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 30.63 |
| PFCF Ratio Avg TTM | 33.00 |
| PFCF Ratio Avg 3Y | 28.84 |
| Current VS TTM Avg | -7.17% |
| Current VS 3Y Avg | +6.21% |
| Current VS 5Y Avg | -4.81% |
A Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.50 |
| Debt/Equity Ratio Avg TTM | 0.55 |
| Debt/Equity Ratio Avg 3Y | 0.53 |
| Current VS TTM Avg | -9.91% |
| Current VS 3Y Avg | -4.76% |
| Current VS 5Y Avg | -2.91% |
A PEG Ratio Metrics
| PEG Ratio | 9.41 |
| PEG Ratio Avg TTM | 9.41 |
| PEG Ratio Avg 3Y | 9.41 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
A FCF Yield
| FCF Yield | 3.26% |
| FCF Yield Avg TTM | 3.06% |
| FCF Yield Avg 3Y | 3.54% |
| Current VS TTM Avg | +6.40% |
| Current VS 3Y Avg | -7.81% |
| Current VS 5Y Avg | +1.46% |
A Earnings Yield
| Earnings Yield | 3.68% |
| Earnings Yield Avg TTM | 3.44% |
| Earnings Yield Avg 3Y | 3.39% |
| Current VS TTM Avg | +6.84% |
| Current VS 3Y Avg | +8.53% |
| Current VS 5Y Avg | +16.45% |
A EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 25.74 |
| Ev/Ebit Ratio Avg TTM | 26.26 |
| Ev/Ebit Ratio Avg 3Y | 27.11 |
| Current VS TTM Avg | -1.97% |
| Current VS 3Y Avg | -5.07% |
| Current VS 5Y Avg | -11.03% |
A EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 21.51 |
| Ev/Ebitda Ratio Avg TTM | 21.11 |
| Ev/Ebitda Ratio Avg 3Y | 21.69 |
| Current VS TTM Avg | +1.87% |
| Current VS 3Y Avg | -0.83% |
| Current VS 5Y Avg | -6.96% |
A EV/Assets Ratio Metrics
| Ev/Assets Ratio | 3.06 |
| Ev/Assets Ratio Avg TTM | 3.06 |
| Ev/Assets Ratio Avg 3Y | 3.38 |
| Current VS TTM Avg | +0.09% |
| Current VS 3Y Avg | -9.54% |
| Current VS 5Y Avg | -17.59% |
A EV/Sales Ratio Metrics
| Ev/Sales Ratio | 5.53 |
| Ev/Sales Ratio Avg TTM | 5.56 |
| Ev/Sales Ratio Avg 3Y | 5.75 |
| Current VS TTM Avg | -0.45% |
| Current VS 3Y Avg | -3.87% |
| Current VS 5Y Avg | -10.95% |
A Current Ratio Metrics
| Current Ratio | 1.96 |
| Current Ratio Avg TTM | 2.02 |
| Current Ratio Avg 3Y | 2.17 |
| Current VS TTM Avg | -3.21% |
| Current VS 3Y Avg | -9.78% |
| Current VS 5Y Avg | -11.18% |
A Quick Ratio Metrics
| Quick Ratio | 1.52 |
| Quick Ratio Avg TTM | 1.54 |
| Quick Ratio Avg 3Y | 1.63 |
| Current VS TTM Avg | -1.62% |
| Current VS 3Y Avg | -6.89% |
| Current VS 5Y Avg | -9.79% |
A ROIC Metrics
| ROIC | 12.57% |
| ROIC Avg 3Y | 13.57% |
| ROIC Avg 5Y | 12.73% |
| Current VS 3Y Avg | -7.35% |
| Current VS 5Y Avg | -1.23% |
| Current VS 10Y Avg | +18.27% |
A Return on Assets Metrics
| ROA | 10.24 |
| ROA Avg TTM | 10.56 |
| ROA Avg 3Y | 11.14 |
| Current VS TTM Avg | -3.03% |
| Current VS 3Y Avg | -8.06% |
| Current VS 5Y Avg | -2.97% |
A Return on Equity Metrics
| ROE | 19.33 |
| ROE Avg TTM | 20.59 |
| ROE Avg 3Y | 21.51 |
| Current VS TTM Avg | -6.12% |
| Current VS 3Y Avg | -10.12% |
| Current VS 5Y Avg | -5.88% |
A Net Profit Margin Metrics
| Net Profit Margin | 18.75% |
| Net Profit Margin Avg TTM | 19.27% |
| Net Profit Margin Avg 3Y | 18.75% |
| Current VS TTM Avg | -2.72% |
| Current VS 3Y Avg | -0.01% |
| Current VS 5Y Avg | +4.52% |
Last Updated: Wednesday, June 10, 2026
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell